Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Transoesophageal Echocardiography in Liver Transplantation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
University of Zurich
ClinicalTrials.gov Identifier:
NCT00547924
First received: October 22, 2007
Last updated: April 9, 2014
Last verified: April 2014
  Purpose

Severe hypotension during reperfusion in liver transplantation is a frequent adverse event. Rare data exist so far about pathophysiology of this phenomenon. The exact role of left ventricular function, which might be impaired causing hypotension, has not been elucidated during the period of reperfusion.

Goal of this study is to:

  • perform transesophageal echocardiography in order to assess systolic and diastolic left ventricular function during reperfusion
  • determine inflammatory mediators in the plasma which could cause left ventricular dysfunction

Condition Intervention
End Stage Liver Disease
Behavioral: Transoesophageal echocardiography

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Transoesophageal Echocardiography in Liver Transplantation: Left Ventricular Function During Reperfusion

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Estimated Enrollment: 17
Study Start Date: April 2006
Study Completion Date: January 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Behavioral: Transoesophageal echocardiography
    Transoesophageal echocardiography in liver transplantation: left ventricular function during reperfusion
  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients on waiting list for liver transplantation

Criteria

Inclusion criteria:

  • Patients on waiting list for liver transplantation.
  • Age: 18-75 years.

Exclusion criteria:

  • Strictures, tumours and diverticula of the oesophagus.
  • History of oesophageal varices with recent bleeding.
  • Oesophageal varices and prothrombin time less than 20% or platetlets les than 30000/ml.
  • Instable cervical spine.
  • Involvement in other studies.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00547924

Locations
Switzerland
University Hospital Zurich, Institute for Anesthesiology
Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Investigators
Principal Investigator: Marco Zalunardo, MD UniversitaetsSpital Zuerich
  More Information

No publications provided

Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT00547924     History of Changes
Other Study ID Numbers: StV 11-2006
Study First Received: October 22, 2007
Last Updated: April 9, 2014
Health Authority: Switzerland: Swissmedic

Additional relevant MeSH terms:
End Stage Liver Disease
Liver Diseases
Digestive System Diseases
Hepatic Insufficiency
Liver Failure

ClinicalTrials.gov processed this record on November 19, 2014